Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF)A, improved the response to ABCP compared to immunotherapy or chemotherapy and conferred a therapeutic benefit in EGFR‐TKI‐resistant NSCLC [6]. The gene discussed is ABCG2; the disease is non-small cell lung carcinoma.